Sarepta Therapeutics (SRPT) shares were boosted Tuesday by analysts with RBC Capital Markets. The team at RBC upgraded the stock to OUTPERFORM from SECTOR PERFORM, based on the accelerated FDA approval of its Duchenne muscular-dystrophy treatment, which analysts say could be a "major game changer." Sarepta shares have more than doubled over the past month, following a challenging start of 2016 for the drugmaker.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.